Hoche Partners Pharma Holding S.A. Amends Procaps Group Stake
Ticker: PRCWF · Form: SC 13D/A · Filed: Oct 28, 2024 · CIK: 1863362
Sentiment: neutral
Topics: schedule-13d, amendment, ownership-change
TL;DR
Hoche Partners Pharma Holding S.A. updated its stake in Procaps Group, S.A. on 10/28/2024.
AI Summary
Hoche Partners Pharma Holding S.A. filed an amendment (No. 11) to its Schedule 13D on October 28, 2024, regarding its holdings in Procaps Group, S.A. The filing indicates a change in the reporting person's beneficial ownership of the ordinary shares of Procaps Group, S.A.
Why It Matters
This amendment signals a potential shift in the ownership structure or strategy of Procaps Group, S.A., which could impact its stock price and future operations.
Risk Assessment
Risk Level: medium — Changes in significant shareholder filings can indicate shifts in control or strategy, potentially leading to volatility.
Key Players & Entities
- Hoche Partners Pharma Holding S.A. (company) — Reporting Person
- Procaps Group, S.A. (company) — Subject Company
- October 28, 2024 (date) — Filing Date
FAQ
What is the specific nature of the change in beneficial ownership reported by Hoche Partners Pharma Holding S.A.?
The filing is an amendment (No. 11) to a Schedule 13D, indicating a change in the reporting person's beneficial ownership of Procaps Group, S.A. ordinary shares, but the exact details of the change are not specified in the provided text.
Who is the subject company in this filing?
The subject company is Procaps Group, S.A.
What is the CUSIP number for the ordinary shares of Procaps Group, S.A.?
The CUSIP number for the ordinary shares of Procaps Group, S.A. is L7756P 102.
When was this Schedule 13D/A filing made?
This Schedule 13D/A filing was made on October 28, 2024.
What is the principal executive office address for Procaps Group, S.A.?
The principal executive office address for Procaps Group, S.A. is 9 rue de Bitbourg, L-1273 Luxembourg Grand Duchy of Luxembourg.
Filing Stats: 983 words · 4 min read · ~3 pages · Grade level 9.5 · Accepted 2024-10-28 20:42:14
Key Financial Figures
- $0.01 — er) Ordinary Shares, nominal value of $0.01 per share (Title of Class of Securiti
- $20 million — o re-capitalize Procaps, which included $20 million in cash and a commitment to secure anot
Filing Documents
- procaps_13da11.htm (SC 13D/A) — 39KB
- ex99_23.htm (EX-99.23) — 7KB
- 0001019056-24-000303.txt ( ) — 47KB
of the Schedule 13D
Item 7 of the Schedule 13D is hereby amended by adding the following: Exhibit 99.23 — Letter from Hoche Partners Pharma Holding S.A. to the Board of Directors of Procaps Group, S.A. dated October 28, 2024 SIGNATURE After reasonable inquiry and to the best of the Reporting Person’s knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct. Dated: October 28, 2024 hoche partners pharma holding s.a. By: /s/ Roman Sokolowski Name: Roman Sokolowski Title: Director Stonehage Fleming Corporate Service Luxembourg S.A., Director By: /s/ Alexander Ludbrook - Miles Name: Alexander Ludbrook - Miles Title: Director By: /s/ Ariane Vansimpsen Name: Ariane Vansimpsen Title: Director